Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
risperidone + moxifloxacin
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Intravenous, Ophthalmic
01
Overview
Risperidone + moxifloxacin is a combination of two pharmaceutical agents with distinct mechanisms and indications. Risperidone is an atypical (second-generation) antipsychotic primarily used to treat schizophrenia, bipolar disorder, and irritability associated with autism. It acts mainly by antagonizing dopamine D2 receptor and serotonin 5-HT2A receptor in the brain, thereby modulating neurotransmitter activity implicated in psychosis and mood disorders[1][4][5]. Moxifloxacin is a broad-spectrum fluoroquinolone antibiotic indicated for the treatment of various bacterial infections. Its bactericidal action results from inhibition of bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and cell division in bacteria[2][3][6]. This combination does not represent a standard or approved fixed-dose product; each drug retains its individual primary indication.
- Brand names
- RisperdalAvelox
- Other names
- risperidone/moxifloxacin
02
Targets
HTR2A (Serotonin receptor 5-HT2A)KCNH2 (Voltage-gated potassium channel subfamily H member 2)Topo IV (Bacterial Topoisomerase IV)DRD2 (Dopamine D2 Receptor)DNA gyrase
Beyond the preview
Go deeper on risperidone + moxifloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on risperidone + moxifloxacin.